A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Vilazodone (VIIBRYD)

Vilazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies (14)].

First FDA approval2011-04-29
Generic availableYes · 5 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$63.3M in CY2024 Part D spend560K claims · 123K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.858/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.962
Across all dosage forms in distribution.
Highest NADAC
$1.21
Range is tight.
Plans with PA
147 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Vilazodone used for?

Vilazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies (14)].

Is there a generic for Vilazodone?

Yes. 15 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Vilazodone?

Across 329 Part D plans, Vilazodone averages $0.962/unit (NADAC). Lowest available: $0.858/unit. Highest in distribution: $1.21/unit.

Is Vilazodone on the FDA shortage list?

No. Vilazodone is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.